Member- Sep 21, 2016
- 1,051
- Tinnitus Since
- 2011 - T, 2016- H, relapsed 2019
- Cause of Tinnitus
- noise-induced
-
This Saturday, November 16, you have the chance to ask Tinnitus Quest anything.
The entire Executive Board, including Dr. Dirk de Ridder and Dr. Hamid Djalilian are taking part.
The event takes place 7 AM Pacific, 9 AM Central, 10 AM Eastern, 3 PM UK (GMT).
➡️ Read More & Register!
Otonomy OTO-413 — Treatment of Hidden Hearing Loss
- Thread starter Michael Larsen
- Start date
- Feb 14, 2020
- 1,630
- Tinnitus Since
- 1-2019
- Cause of Tinnitus
- 20+ Years of Live Music, Motorcycles, and Power Tools
The data looks promising. I'm curious if there is oversight by objective third party experts/researchers in the areas of specialization.
Looking at the corporate presentation @patorjk posted, those are strong results but I wonder if they would have gotten even better results if they had excluded the moderate to severe hearing loss group since that group likely had more inner hair cell loss.
Anyway these results look good. I think the hype train will wake up when more people in more time zones do.
- Feb 14, 2020
- 1,630
- Tinnitus Since
- 1-2019
- Cause of Tinnitus
- 20+ Years of Live Music, Motorcycles, and Power Tools
There is evidence of restoration. They restored some hearing function, which means they restored some hearing structures.
That is what we're all waiting for. Restoration. I don't know about y'all, but I'm dancing around in my underwear.
That is what we're all waiting for. Restoration. I don't know about y'all, but I'm dancing around in my underwear.
- Feb 14, 2020
- 1,630
- Tinnitus Since
- 1-2019
- Cause of Tinnitus
- 20+ Years of Live Music, Motorcycles, and Power Tools
I'd put it closer to 3. If they stick with a 90-day assessment period, the trials should go quickly. They haven't announced a Phase 2 to my knowledge, and FDA Fast Track could help things along.
Warning: speculation ahead...
Phase 2: 2021-Q2 - 2022-Q2
Phase 3: 2023
FDA approval: 2024
I'm going to choose to believe in Fast Track and that it arrives on Christmas Day 2022 along with FX-322.
It's still a very long time. I hope OTO-413 is successful but we would all prefer to take FX-322 if it ends up helping with hyperacusis and tinnitus but at least there are different drugs that are working on different areas in the ear so we would know more about what works and what doesn't.
- May 27, 2020
- 556
- Tinnitus Since
- 2007
- Cause of Tinnitus
- Loud music/headphones/concerts - Hyperacusis from motorbike
Great news. Otonomy is also 50 cents up on NASDAQ since the announcement, although I'm surprised it hasn't gone higher than that.
I would say that's pretty conservative. I would shorten Phase 2 a bit. I would say approval in 2023 is my bet.
- Feb 14, 2020
- 1,630
- Tinnitus Since
- 1-2019
- Cause of Tinnitus
- 20+ Years of Live Music, Motorcycles, and Power Tools
- Feb 14, 2020
- 1,630
- Tinnitus Since
- 1-2019
- Cause of Tinnitus
- 20+ Years of Live Music, Motorcycles, and Power Tools
The important thing here is two hearing drugs with clinically significant outcomes are in the pipeline.
They also did a conference call this morning, it's kind of long but you can listen to it here:
https://edge.media-server.com/mmc/p/nh3ph6tm
- They talk a little bit about the durability (they measured people at day 57 and 85), apparently some patients were still improving at day 85, so that's a good sign.
- They want to see if they can up the dosage for Phase 2. However, they want to examine all the of the data before they make that decision.
- 11 people got a high dose, but only 9 counted for the data in their slides. One of the 2 that didn't get counted didn't get measured at day 57 but did get measured at day 85. At day 85 they saw meaningful improvement.
- The patients took a lot of different tests, requiring hours of their time.
- Lots of data is still left to be processed. We'll probably get another report on the data sometime later.
https://edge.media-server.com/mmc/p/nh3ph6tm
- They talk a little bit about the durability (they measured people at day 57 and 85), apparently some patients were still improving at day 85, so that's a good sign.
- They want to see if they can up the dosage for Phase 2. However, they want to examine all the of the data before they make that decision.
- 11 people got a high dose, but only 9 counted for the data in their slides. One of the 2 that didn't get counted didn't get measured at day 57 but did get measured at day 85. At day 85 they saw meaningful improvement.
- The patients took a lot of different tests, requiring hours of their time.
- Lots of data is still left to be processed. We'll probably get another report on the data sometime later.
We'll unfortunately probably need both.
It's been a roller coaster. As I'm typing this it's now up 9%, but at one point pre-market it was down 10%. The stock was run up around 40-50% in the last month. So it may have been overvalued. It makes me a wonder if something similar will happen to Frequency Therapeutics. It's being run up like crazy right now.
Pre55ure
Member
My understanding is that Otonomy believes that their delivery method is superior to something like FX-322. Is there any information released anywhere on how deep into the cochlea they believe that their drugs can be effective?
Basically, do we know if there is a lower frequency threshold at which OTO-413 starts to become less effective? Or is this the data that would be expected to come out of a more involved phase 2 trial?
Basically, do we know if there is a lower frequency threshold at which OTO-413 starts to become less effective? Or is this the data that would be expected to come out of a more involved phase 2 trial?
- Aug 5, 2019
- 1,852
- Tinnitus Since
- 05/2019
- Cause of Tinnitus
- Autoimmune hyperacusis from Sjogren's Syndrome
Am I on the only one really satisfied with the fact that the placebos saw zero improvements (in the clinically meaningful sense)? It's not surprising, but it's a pretty big form of validation to people with hidden hearing loss. It doesn't quite validate hyperacusis and tinnitus, but it's a start.
They believe it's superior based on higher concentration for longer because it's in an extended release gel (which mimics repeat dosing even better than Frequency Therapeutics, it's like getting more doses, more often). There is no reason Frequency Therapeutics couldn't later put theirs in an extended release formulation.
This is amazing news!
It seems that they are onto something. I imagine bigger pharmaceutical companies are watching this. If there is a real avenue of treatment the pace of research will skyrocket in the next few years.
It seems that they are onto something. I imagine bigger pharmaceutical companies are watching this. If there is a real avenue of treatment the pace of research will skyrocket in the next few years.
This is about the best thing that could happen. Having the placebos fail means that there tends to be little or no way where those against these types of medicines could consequently criticise their effectiveness and/or validity.
I think that this also validates Otonomy's claims pre-trial that the high dose would provide the greatest response with outcomes and also actually seems safe as well.
Obviously Otonomy has really good claims to proceed with the higher dose and hopefully obtain approval to use an even bigger dose in future trials.
Log in or register to get the full forum benefits!
Similar threads
